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Pathogenesis and clinical manifestations of juvenile 
rheumatoid arthritis
Juvenile rheumatoid arthritis (JRA) is the most common rheumatic 
childhood disease; its onset is before 16 years of age and it persists for 
at least 6 weeks. JRA encompasses a heterogeneous group of diseases 
that is classified according to 3 major presentations: oligoarthritis, 
polyarthritis, and systemic onset diseases. These presentations may 
originate from the same or different causes that involve interaction with 
specific immunogenetic predispositions, and result in heterogeneous 
clinical manifestations. An arthritic joint exhibits cardinal signs of joint 
inflammation, such as swelling, pain, heat, and loss of function; any 
joint can be arthritic, but large joints are more frequently affected. 
Extra-articular manifestations include high fever, skin rash, serositis, 
and uveitis. The first 2 types of JRA are regarded as T helper 1 (Th1) 
cell-mediated inflammatory disorders, mainly based on the abundance 
of activated Th1 cells in the inflamed synovium and the pathogenetic 
role of proinflammatory cytokines that are mainly produced by Th1 
cell-stimulated monocytes. In contrast, the pathogenesis of systemic 
onset disease differs from that of other types of JRA in several respects, 
including the lack of association with human leukocyte antigen type 
and the absence of autoantibodies or autoreactive T cells. Although the 
precise mechanism that leads to JRA remains unclear, proinflammatory 
cytokines are thought to be responsible for at least part of the clinical 
symptoms in all JRA types. The effectiveness of biologic therapy in 
blocking the action of these cytokines in JRA patients provides strong 
evidence that they play a fundamental role in JRA inflammation. 
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that includes all forms of chronic childhood arthritis of unknown 
origin. JRA is the most common chronic rheumatic illness 
in children and is a significant cause of both short- and long-
term disabilities. The heterogeneity of this disease suggests that 
different factors likely contribute to its pathogenesis. The current 
Introduction
Juvenile rheumatoid arthritis (JRA) is a generic term for arthritis 
that has an onset before the age of 16 and persists for more than 6 
weeks. The JRA nomenclature represents an exclusion diagnosis 922      YS Hahn, and JG Kim • Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis
understanding of JRA indicates that it arises in a genetically 
susceptible individual due to environmental factors
1-3). Moreover, 
it has been proposed that an antigen-driven autoimmune process 
mediates the inflammatory pathology of some cases of arthritis 
(e.g., oligoarthritis, polyarthritis). In contrast, there are no signs 
of lymphocyte-mediated, antigen-specific immune responses in 
individuals with systemic onset disease. Recent investigations in 
the pathophysiology of systemic onset disease have indicated that 
this disorder is due to an uncontrolled activation of the innate 
immune system
4). Regardless of the differences in the underlying 
pathogenesis of the various types of JRA, proinflammatory 
cytokines are consistently overproduced and are related to the 
clinical manifestations in all types of JRA. Modulation of these 
cytokines results in improvement of clinical outcome
5), which 
strongly suggests that these cytokines play important roles in JRA. 
Currently, 3 separate classification systems are used to categorize 
individuals under 16 years of age with chronic arthritis. These 
include the American College of Rheumatology (ACR)
6), the 
European League Against Rheumatism (EULAR)
7), and the 
International League of Associations for Rheumatology (ILAR)
8) 
criteria. Because none of these systems are perfect models, some 
JRA patients fulfill criteria for more than one subtype, whereas 
others are difficult to classify into any of the specific subgroups. 
Both the ACR and EULAR criteria are based solely on the onset 
type as it is manifested during the first 6 months of disease, whereas 
the ILAR criteria also include the course type over an unknown 
period of time thereafter, in order to further distinguish the group 
of patients with oligoarticular disease. 
Epidemiological studies of JRA have been hampered by a lack 
of standardized criteria and case ascertainment, which has resulted 
in wide-ranging results. For instance, the reported prevalence 
of JRA ranges from 0.07 to 4.01 per 1,000 children, and the 
annual worldwide incidence varies from 0.008 to 0.226 per 1,000 
children
9). However, the actual incidence and prevalence of JRA 
in the Asian population, including Korean children, have not been 
well quantified because most large epidemiologic studies performed 
to date have been based on populations of patients who were mainly 
of European ancestry. Of note, one previous study from Japan 
showed that JRA had a relatively low overall prevalence among the 
population
10), suggesting lower incidence and prevalence in children 
of Asian origin than those of European origin. Furthermore, there 
are significant differences in JRA subtype distribution among the 
different ethnic groups as well
11). 
Pathogenesis
1. Associations of human leukocyte antigen (HLA) and 
non-HLA molecules in JRA
The genetic basis of JRA is complex, but it has been estimated 
that the sibling recurrence risk of developing the disease is around 
15
12). To date, only 2 genetic risk factors, HLA and protein 
tyrosine phosphatase non-receptor 22 (PTPN22) genes, have been 
unequivocally confirmed as JRA susceptibility genes in multiple 
populations. The most well-established genetic factors for JRA are 
the HLA genes. Because the main function of HLA molecules is 
presenting antigenic peptides to T cells, HLA associations with 
JRA imply that this disease may be caused by an unidentified 
arthritogenic antigen. Many associations between subsets of JRA 
and the various HLA molecules have been described previously in 
the literature
13-15). However, both the strength of these associations 
and the associated alleles vary between the JRA subtypes. 
Specifically, oligoarthritis has been consistently associated with 
HLA-A2, HLA-DRB1*11, and HLA-DRB1*08. Rheumatoid 
factor (RF)-positive polyarthritis is reportedly associated with HLA-
DR4 in children, similarly to in adults. Moreover, the presence of 
HLA-B27 confers an increased risk of enthesitis-related arthritis. 
PTPN22 encodes a lymphoid-specific phosphatase (Lyp). A variant 
in the coding region of this gene, which is reportedly associated 
with a number of autoimmune diseases, has also been identified as 
a susceptibility locus for JRA
16). The effect size of PTPN22 varies 
somewhat between JRA subtypes but, in general, is more consistent 
than that of HLA genes. A few other genes, including macrophage 
inhibitory factor, interleukin (IL)-6, IL-10, and tumor necrosis 
factor (TNF)-α , have also been associated with JRA in different 
populations and subtypes
17). However, these discussed genes may 
collectively account for only a small proportion of the total genetic 
contribution to disease. 
2. Inflammatory mediators of joint damage
Synovial membranes of JRA patients contain activated T and B 
cells, plasma cells, and activated macrophages that are recruited via 
an intense neovascularization process. Host tissue cells, including 
activated synovial fibroblasts, chondrocytes, and osteoclasts, 
mediate cartilage and bone destruction. It has been established 
that the recruitment, activation, and effector function of each of 
these contributor lineages are directed principally by a network of 
cytokines (Fig. 1).
Antigen-specific T cells appear to play a central role in the 
pathogenesis of arthritis subtypes within JRA. T-cell infiltrates 
are composed predominantly of T helper 1 (Th1) cells, which Korean J Pediatr 2010;53(11):921-930• DOI: 10.3345/kjp.2010.53.11.921    923
express an activated memory phenotype and high concentrations 
of chemokine receptors
18, 19). Th1 cells stimulate B cells, monocytes, 
macrophages, and synovial fibroblasts to produce immunoglobulins 
and inflammatory mediators. Activated B cells produce immu-
noglobulins, including RF and antinuclear antibodies (ANAs). The 
precise pathogenic role of RF remains unknown, but it may involve 
the activation of complement through the formation of immune 
complexes. ANAs, which are mainly associated with early-onset 
oligoarthritis, have been reported to react against different nuclear 
targets, none of which are specific for JRA. Activated macrophages, 
lymphocytes, and fibroblasts, as well as their products including 
vascular endothelial growth factor (VEGF) and osteopontin, can 
stimulate angiogenesis. VEGF is highly expressed in synovial 
tissue
20), whereas osteopontin is raised in synovial fluid and tissue, 
and correlates with new vascularisation
21).
TNF-α  and IL-1 produced by activated monocytes, macro-
phages, and synovial fibroblasts likely have primary roles in the 
pathogenesis of JRA. These cytokines are detected in synovial 
fluids or tissues in a majority of JRA patients
22, 23), and are known 
to stimulate mes  enchymal cells, such as synovial fibroblasts, 
osteoclasts, and chondrocytes, to release tissue-destroying matrix 
metalloproteinases
24). TNF-α  and IL-1 also inhibit synovial 
fibroblasts from producing tissue inhibitors of metalloproteinases. 
Collectively, these dual actions seem to lead to joint damage. Indeed, 
data from animal models strongly suggest TNF-α  and IL-1 play roles 
in JRA. For instance, transgenic mice that expressed a deregulated 
human TNF-α  gene spontaneously developed an inflammatory 
and destructive polyarthritis similar to JRA
25). Moreover, blocking 
TNF-α  with either a soluble TNF-receptor fusion protein or 
monoclonal antibodies also ameliorated disease activity in mice 
with type II collagen-induced arthritis
26, 27). Injection of IL-1 into 
the knee joints of rabbits has been demonstrated to result in the 
degradation of cartilage
28), whereas the injection of antibodies 
against IL-1 ameliorated collagen-induced arthritis in mice and 
decreased the damage to cartilage
29). 
IL-6 is a multifunction cytokine that has a wide range of bio-
lo  gical activities in various target cells and regulates immune 
re  s  ponses, acute phase reactions, hematopoiesis, and bone 
metabolism
30). Circulating levels of IL-6 are markedly elevated in 
patients with JRA, and are associated with laboratory and clinical 
variables of disease activity
31, 32). IL-6 stimulates hepatocytes and 
induces the production of several acute-phase proteins, such as 
C-reactive protein (CRP)
33). Thus, elevated levels of IL-6 in serum 
correlate with CRP levels in JRA patients with active disease. 
IL-17 is produced by Th17 cells, and induces a massive tissue 
reaction due to the broad distribution of the receptors to this 
cytokine. Recent evidence suggests that IL-17-producing Th17 cells 
have a crucial role in autoimmune inflammation
34). In particular, 
IL-17 promotes a proinflammatory cytokine environment in the 
joint, stimulating macrophage production of TNF-α  and IL-
1
35), and synergizes with these cytokines to increase IL-6 and 
IL-8 production
36, 37). In addition, IL-17 contributes directly 
to joint destruction by upregulating matrix metalloproteinases 
and stimulating osteoclastogenesis through receptor activation 
of nuclear factor-κ B ligand (RANKL) induction
38-40). IL-17 is 
increased in JRA patients with active disease compared with 
levels in individuals in remission
41). Data from animal models also 
suggest IL-17 has a role in cartilage degradation. For instance, IL-
17-deficient mice were demonstrated to be resistant to induction 
of collagen-induced arthritis
42). Moreover, joint inflammation and 
cartilage and bone destruction were suppressed after administration 
of anti-IL-17 antibodies in mice with collagen-induced arthritis
43).
3. Unique inflammatory profile of systemic onset disease
The pathogenesis of systemic onset disease differs from that 
of other types of JRA in several respects, such as the lack of asso-
ciation with HLA type
44) and the absence of autoantibodies and 
autoreactive T cells
45). Thus, patients with systemic onset disease 
do not show signs of lymphocyte-mediated antigen-specific 
immune responses. Instead, the typical clinical signs of systemic 
onset disease are associated with granulocytosis, thrombocytosis, 
and upregulation of acute-phase reactants, which indicate an 
uncontrolled activation of the innate immune system
4). During 
both the initial manifestation and the flares of systemic onset 
disease, there is a perivascular infiltration of neutrophils and 
Fig. 1. Cytokine signaling pathways involved in JRA. Interactions among 
macrophages, T cells, B cells, and non-hematopoietic cells including 
fibroblasts are important in the pathogenesis of JRA. These interactions 
are facilitated by the actions of cytokines that induce the production of 
other proinflammatory cytokines. 924      YS Hahn, and JG Kim • Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis
monocytes producing proinflammatory cytokines involved in the 
pathogenesis of this disease
46). The predominant role of the innate 
immune system in systemic onset disease is also underscored by 
the high expression and serum concentrations of the calcium-
binding proteins S100A8, S100A9, and S100A12, which are 
speci  fically secreted during activation of neutrophilic granulocytes 
and monocytes
47). The extraordinarily high serum concentrations 
of these proteins are closely associated with the disease activity of 
systemic onset disease, and are not found in patients with other 
forms of inflammatory arthritis or other autoimmune or infectious 
diseases
48, 49). S100 proteins exhibit proinflammatory effects on 
leukocytes and endothelial cells, and are thus likely to be directly 
involved in the inflammatory process of systemic onset disease
50, 51).
Recent data indicate that IL-1 has a prominent role in systemic 
onset disease. Treatment with IL-1 receptor antagonist has been 
shown to reduce the clinical and laboratory features of disease 
activity in patients with systemic onset disease who show resistance 
to anti-TNF-α  treatment
52). In addition, activated monocytes from 
patients with systemic onset disease secrete significantly higher 
amounts of IL-1 in comparison with secreted levels from monocytes 
of healthy controls, whereas release of TNF-α  and IL-6 is not 
significantly different between these groups. Another member of 
the IL-1 cytokine family, IL-18, was found to be extremely elevated 
in patients with adult-onset Still’s disease compared with levels in 
patients with a variety of other rheumatic diseases and in healthy 
controls
53). An equally dramatic rise in IL-18 concentration has been 
found in serum from children with systemic onset disease, whereas 
levels in children with polyarticular or oligoarticular disease were 
not significantly higher than levels in the healthy controls
54). 
Moreover, IL-18 concentrations are significantly higher in patients 
with either serositis or hepatosplenomegaly than in patients without 
these manifestations. 
The circulating concentration of IL-6 is noticeably increased 
in patients with systemic onset disease and correlates with the 
extent of joint involvement
55, 56). In addition, IL-6 concentration is 
significantly higher in the synovial fluid of patients with systemic 
onset disease than in patients with other JRA subtypes
57). The 
overproduction of IL-6 may explain many of the extra-articular 
manifestations of this disease, including microcytic anemia
58) and 
growth impairment
59). Treatment with a monoclonal antibody 
directed against the IL-6 receptor is associated with pronounced 
clinical improvement and the reestablishment of normal levels of 
acute-phase reactants in patients with systemic onset disease
60).
The clinical and pathologic manifestations of macrophage 
activation syndrome (MAS) are thought to result from the 
activation and uncontrolled proliferation of T-lymphocytes and 
well-differentiated macrophages, which leads to an unrestricted 
release of inflammatory cytokines, such as TNF-α , IL-1, and IL-
6. However, the cause of the immunologic derangement associated 
with MAS is unknown. Recently, studies have revealed markedly 
decreased natural killer cell function and, in some cases, depressed 
perforin expression in patients with systemic onset disease; it has 
been suggested that these abnormalities may explain the distinctive 
susceptibility of these patients to developing MAS
61, 62).
4. Anti-inflammatory mediators in JRA
The two most well-known anti-inflammatory cytokines 
associated with JRA are IL-10 and IL-4. IL-10 has been shown 
to reverse cartilage degradation mediated by antigen-stimulated 
mononuclear cells in adult patients with arthritis
63). In addition, a 
single nucleotide polymorphism connected to lower production 
of IL-10 is associated with a more severe type of arthritis
64). IL-4 
inhibits the activation of Th1 cells, which in turn decreases the 
production of TNF-α  and IL-1 and inhibits cartilage damage
65). 
IL-4 and IL-10 cooperate to inhibit the production of inflammatory 
cytokines, including IL-6 and IL-8
66). Higher levels of IL-4 and 
IL-10 mRNA within a joint are allied with a milder oligoarticular 
course and non-erosive disease
67). 
Foxp3+CD4+CD25+ regulatory T cells (Tregs) are important 
for controlling inflammatory processes
68). In humans, an X-linked 
genetic defect in Foxp3 is the underlying cause of a condition that 
presents with multiple autoimmune conditions, which is named the 
immuno-dysregulation, polyendocrinopathy, enteropathy (IPEX) 
syndrome
69). Less serious defects in Treg function have also been put 
forward as a cause of failed tolerance in several human autoimmune 
diseases. However, there is currently no evidence suggesting  de-
fects in Treg function in JRA, although the number of synovial 
Tregs is significantly lower in patients with extended oligoarthritis 
compared with the number in patients with a milder course of 
the disease
70). Moreover, a higher number of Tregs have been 
found within joints of JRA patients compared with the number in 
peripheral blood
71), which indicates an enrichment of Tregs within 
the inflamed joints. However, it appears that high numbers of 
regulatory cells in the joint fail to moderate the local inflammatory 
process. This finding may be related to effector T cell resistance, 
suppression at the site of inflammation
72), or the attenuation of Treg 
function by local dendritic cell-derived cytokines, such as IL-6
73). 
Clinical manifestations
1. Arthritis
An arthritic joint exhibits a number of cardinal signs of inflam-Korean J Pediatr 2010;53(11):921-930• DOI: 10.3345/kjp.2010.53.11.921    925
mation, such as swelling, erythema, heat, pain, and loss of function 
(Fig. 2, 3). Involved joints are often warm, but are not typically 
erythematous. Children with arthritis may not complain of pain 
while at rest, but active or passive motion typically elicits pain. 
Joint tenderness is usually maximal at the joint line or just over 
the hypertrophied, inflamed synovium. Of note, bone pain or 
tenderness is not characteristic of JRA and may instead indicate 
the possibility of a malignancy involving bone. Morning stiffness 
and gelling following inactivity are common manifestations of 
joint inflammation, but young children infrequently describe these 
symptoms. Often, young children do not complain of pain and 
instead refuse to use the affected joint entirely. 
Any joint can be affected by JRA, but large joint are more fre-
quently involved than smaller joints
74). However, small joints of 
the hands and feet are also affected, particularly in polyarticular 
onset disease
75). Of note, cricoarytenoid arthritis is unusual but 
may be responsible for acute airway obstruction. Inflammation 
of the synovial joints in the middle ear has also been detected by 
tympanometric studies
76). The temporomandibular joint and 
the cervical, thoracic, and lumbar spine should also be examined 
in the case of JRA. JRA often affects the cervical spine, and the 
most common changes in the upper cervical spine are anterior 
atlantoaxial subluxation and impaction
77, 78). Subluxation of the 
atlantoaxial joints may also occur, rendering the affected child at 
risk of injury in an accident or upon attempted intubation prior 
to receiving general anesthesia. Scoliosis, which possibly reflects 
asymmetric thoracolumbar apophyseal joint inflammation, may 
also occur in children with JRA. Small outpouchings of symovium 
are not uncommon in individuals with JRA and are particularly 
evident at the extensor hood of the proximal interphalangeal 
joint and around the wrist or ankle. A synovial cyst in the 
antecubital area or anterior to the shoulder may be the initial or sole 
presentation of JRA.
Oligoarticular disease develops in at least 50% of children with 
JRA during the first 6 months of disease. This subtype is the only 
form of JRA without an adult equivalent. Oligoarticular disease 
affects up to 4 joints at presentation, with the knee joints mostly 
affected, followed by the ankles
74). In contrast, this subtype almost 
never affects the hips, and rarely the smaller joints of the hands 
and feet. Oligoarticular disease is characterized by asymmetric 
arthritis, early onset (before 6 years of age), female predilection, 
high frequency of positive ANAs, and a high risk of iridocyclitis. 
The ILAR classification distinguishes 2 further categories within 
the oligoarthritis subtype: persistent oligoarthritis, in which the 
disease is confined to 4 or fewer joints, and extended oligoarthritis, 
in which the arthritis extends to more than 4 joints after the first 
6 months of disease. Up to 50% of oligoarticular patients develop 
extended disease, and 30% will do so in the first 2 years after 
diagnosis. The risk factors for extended disease include involvement 
of an upper limb joint and elevated erythrocyte sedimentation rate 
(ESR) at onset
79). 
Polyarticular disease is defined as the presence of arthritis in 5 or 
more joints during the first 6 months of disease. The arthritis may 
be symmetrical and usually involves the large and small joints of the 
hands and feet, although the axial skeleton, including the cervical 
Fig. 2. Swelling and flexion contracture of the right knee of a repre-
sentative patient with oligoarticular disease.
Fig. 3. Polyarticular disease affects the joints of the wrist and hand. The 
proximal and distal interphalangeal joints are erythematous. There are 
flexion contractures of the fingers.926      YS Hahn, and JG Kim • Pathogenesis and clinical manifestations of juvenile rheumatoid arthritis
spine and the temporomandibular joints, may also be affected. This 
subtype includes children with both RF-negative and RF-positive 
diseases. Both types affect girls more frequently than boys. RF-
negative patients often develop polyarthritis in early childhood, 
whereas RF-positive patients instead develop arthritis during late 
childhood and adolescence. Three distinct subsets of RF-negative 
polyarthritis have been identified. The first subset is a form that 
resembles early-onset oligoarticular disease, except for the number 
of joints affected in the first 6 months of disease. The second subset 
is similar to adult-onset RF-negative rheumatoid arthritis, and is 
characterized by overt symmetric synovitis of large and small joints, 
onset during school age years, increased ESR, negative ANA, and 
variable outcome. Finally, the third subset is a form known as dry 
synovitis, which shows negligible joint swelling but stiffness and 
flexion contractures
80). RF-positive patients are primarily adolescent 
girls with symmetric small joint involvement and early-onset 
erosive synovitis. Approximately a third of these patients develop 
subcutaneous nodules (non-tender, firm lesions over pressure points 
and tendon sheaths), typically in the board of the forearm and 
elbow. The HLA associations in these patients are the same as in 
adult seropositive rheumatoid arthritis patients and likely represent 
the early expression of adult rheumatoid arthritis. 
2. Systemic extra-articular manifestations
Systemic involvement may precede the development of overt 
arthritis by weeks, months, or rarely years. In the right clinical 
setting, with characteristic fever and classic rash, the diagnosis of 
probable systemic onset disease may be made, and confirmation 
of the diagnosis can follow when persistent arthritis develops
81). 
The arthritis associated with systemic onset disease is usually 
polyarticular affecting both large and small joints. Asymmetric, 
oligoarticular arthritis is less common. The systemic pattern is 
prominent during the first 4-6 months of disease and rarely occurs 
for the first time during the later course of disease. 
The most prominent feature of systemic involvement is a high 
spiking fever
82). Specifically, the temperature of an individual 
typically rises to 39℃ or higher on a daily or twice-daily basis, 
followed by a rapid return to the baseline temperature or below (Fig. 
4). Although this quotidian pattern is highly suggestive of systemic 
onset disease, patients may not present this fever pattern. Fever may 
occur at any time of the day, but characteristically presents in the 
late afternoon to evening in conjunction with the rash. Moreover, 
the temperature may be subnormal in the morning. During 
episodes of fever, an affected child commonly appears ill when 
chills are present, but then appears well when the fever breaks. 
Fever associated with systemic onset disease often responds poorly 
to the commonly prescribed nonsteroidal anti-inflammatory drugs 
(NSAIDs), even at high doses. 
In the case of systemic onset disease, intermittent fever is almost 
always accompanied by the classic rash
82). The classic rash is 
evanescent (usually coming and going with the fever spikes) and 
consists of discrete, circumscribed, salmon-pink macules (2-mm to 
10-mm in size) that may be surrounded by a ring of pallor or may 
develop central clearing (Fig. 5). Lesions are most common on the 
trunk and proximal extremities, including the axilla and inguinal 
areas, but can also develop on the face, palms, or soles of affected 
individuals. The rash tends to be migratory and is strikingly 
evanescent: individual lesions last for up to a few hours and leave 
no residua. Moreover, the rash may be much more persistent in 
children who are systemically very ill, and may reappear with each 
systemic exacerbation. Such rash also occurs very rarely in children 
with polyarticular onset disease, and likely never occurs in those 
with classic oligoarthritis. Individual lesions may be elicited either 
by rubbing and/or scratching the skin (the so-called Koebner 
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Fig. 4. High intermittent fever in a representative patient with systemic 
onset disease.
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response), by a hot bath, or by psychological stress. The rash is 
occasionally pruritic but is never purpuric. 
Pericarditis and pericardial effusions are especially common 
in children with systemic onset disease
83, 84). Pericarditis may 
precede the development of arthritis or may occur at any time 
during the course of disease, and is usually accompanied by a 
systemic exacerbation of disease. Pericarditis tends to occur in 
older children, but it is not related to sex, age at onset, or severity 
of joint disease. Most pericardial effusions are asymptomatic, 
although some children have dyspnea or precordial pain that 
may be transferred to the back, shoulder, or neck. In many cases, 
pericardial effusions develop insidiously, may not be accompanied 
by obvious cardiomegaly or electrocardiographic changes, and 
escape recognition except by echocardiography. Examination 
of affected patients may disclose diminished heart sounds, 
tachycardia, cardiomegaly, and a pericardial friction rub, usually at 
the left lower sternal border. Pneumonitis or pleural effusions may 
also occur with carditis, or may be asymptomatic and detected only 
as incidental findings on chest radiographs. Pulmonary rheumatoid 
nodules that are described in adult rheumatoid arthritis are rare in 
childhood. 
Another characteristic of systemic onset disease is enlargement of 
lymph nodes and spleen, either alone or in combination. Marked 
symmetric lymphadenopathy is particularly common in the 
anterior cervical, axillary, and inguinal areas, and may suggest the 
diagnosis of lymphoma. Mesenteric lymphadenopathy may cause 
abdominal pain or distention and lead to an erroneous diagnosis 
of an acute surgical abdomen. Splenomegaly is generally most 
prominent within the first years after onset of systemic onset disease. 
The degree of splenomegaly may be extreme, but it is uncommonly 
associated with Felty’s syndrome (splenic neutropenia)
85). Hepa-
tomegaly is less common than splenomegaly. Furthermore, 
moderate to severe enlargement of the liver is often associated with 
only mild derangement of function and relatively nonspecific 
histopathologic changes
86). However, massive enlargement of the 
liver is usually accompanied by abdominal distention and pain. 
Progressive hepatomegaly is characteristic of secondary amyloidosis, 
which refers to the tissue deposition of the fibrillar protein amyloid. 
MAS is a rare but life-threatening complication of systemic onset 
disease that is characterized by demonstration of histiophagocytosis 
in bone marrow
87). The main manifestations of MAS include fever, 
hepatosplenomegaly, lymphadenopathy, severe cytopenias, serious 
liver disease, and disseminated intravascular coagulation. The 
pathognomonic feature of MAS is often found in bone marrow, 
which includes numerous, well-differentiated macrophages 
phagocytosing hematopoietic elements. It has been estimated 
that MAS develops in at least 10% of patients with systemic onset 
disease, although the true incidence of MAS might be much higher 
since there are no validated diagnostic criteria for this syndrome 
and mild instances are not always recognized
88). MAS bears close 
resemblance to a group of histiocytic disorders collectively known as 
hemo  phagocytic lymphohistiocytosis (HLH)
89). Triggers of MAS 
include a preceding viral illness and the addition of or a change in 
medications, especially including NSAIDs, intramuscular gold 
injections, sulfasalazine, and more recently etanercept
90). 
3. Uveitis
Chronic, anterior, nongranulomatous uveitis (iridocyclitis) 
develops in up to 21% of patients with oligoarticular disease and 
10% of patients with polyarticular disease
91). However, no patients 
with systemic onset disease have been diagnosed as having uveitis 
to date
92). The only known independent risk factor for developing 
uveitis is a positive ANA test. The onset of chronic uveitis is typically 
insidious and often entirely asymptomatic, although up to one half 
of affected children have some symptoms attributable to uveitis 
(e.g., pain, redness, headache, photophobia, change in vision) later 
in the course of their disease. Uveitis may be present at the time 
of diagnosis, may develop during the course of JRA, or may be an 
initial manifestation of JRA that is usually detected in the course 
of routine ophthalmologic examination. JRA patients should be 
screened routinely to prevent delay in diagnosis of uveitis. The 
earliest signs of uveitis on slit-lamp examination are the presence 
of inflammatory cells and increased protein concentration in the 
aqueous humor of the anterior chamber of the eye. In addition, 
deposition of inflammatory cells on the inner surface of the cornea 
(keratopunctate deposits) may develop later during the course 
of disease. Complications of uveitis include posterior synechiae, 
cataracts, band keratopathy, glaucoma, and visual impairment.
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